


IFW

1647



Attorney Docket No.: 6169.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor Application of: Liselotte Bjerre Knudsen

Application No.: 09/800,541

Group Art Unit: 1647

Filed: March 7, 2001

Examiner: Romeo, David S.

Confirmation No. 4130

For: Lowering Serum Lipids

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.


This information disclosure statement is being filed **after** the period set forth in 37 C.F.R.

1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,


Date: March 12, 2007

  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Inc.  
Customer Number 23650  
(609) 987-5800

**Use the following customer number for all correspondence regarding this application.**

**23650**

PATENT TRADEMARK OFFICE



Attorney Docket No.: 6169.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Liselotte Bjerre Knudsen

Serial No.: 09/800,541

Group Art Unit: 1647

Filed: March 7, 2001

Examiner: Romeo, David S.

Confirmation No. 4130

For: Lowering Serum Lipids

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

MS: IDS  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement (in duplicate)
2. Form PTO-1449
3. Copy of References (18)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

MS: IDS  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on **March 12, 2007**

Csaba Attila Szakolczai  
(name of person mailing paper)

/Csaba Attila Szakolczai/  
(signature of person mailing paper)


 U.S. DEPARTMENT OF COMMERCE  
 PATENT AND TRADEMARK OFFICE
Atty. Docket No. **6169.200-US**Serial No. **09/800,541**
 INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant **Knudsen, Liselotte Bjerre**Filing Date **March 7, 2001**Group **1647**

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	99/07404		WO				
	99/25727		WO				
	99/25728		WO				


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Larsen, P. et al., Diabetes, Vol. 50, pp. 25230-9 (November 2001)
	Elbrond, B. et al., Diabetes Care, Vol. 25 (8), pp. 1398-1404 (August 2002)
	Rolin, B. et al., ADA 2001, P1294 (2001)
	Rolin, B. et al., Diabetes Abstract Book, Vol. 50 (Suppl. 2), pg. A312 (June 2001)
	Sturis, J. et al., EASD2000, P559
	42nd EASD Meeting 2006 Website Screenshot
	Montrose-Rafizadeh, C. et al., J of Biol Chem, Vol. 272 (34), pp. 21021-6 (1997)
	Gardner, S. et al., Pharmacotherapy, Vol. 16 (3), pp. 419-23 (1996)
	Harder, H. et al., Diabetes Care, Vol. 27 (8), pp. 1915-21 (August 2004)
	Ribel, U. et al., Euro J. of Pharma, Vol. 451, pp. 217-25 (2002)
	Summary of the Second Report of the NCEP, JAMA, Vol. 269 (23), pp. 3015-23 (June, 1993)
	Gotto, Antonio Jr., Circulation, Vol. 96 (12), pp. 4424-30 (December, 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


 FORM TQ-1449  
(Rev. 1-32)

 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

 Atty. Docket No. **6169.200-US**

 Serial No. **09/800,541**

 INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

 Applicant **Knudsen, Liselotte Bjerre**

 Filing Date **March 7, 2001**

 Group **1647**

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Thompson, R. et al., Diabetes Care, Vol. 21 (6), pp. 987-93 (June 1998)
		Amylin Pharmaceuticals Opposition to Novo Nordisk A/S Patent 2107/1263458
		Opposition By Novo Nordisk A/S for European Patent No. 1246638

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.